DK2444814T5 - Biomarkør for mentale lidelser, herunder kognitive lidelser, og fremgangsmåde ved anvendelse af biomarkøren til påvisning af mentale lidelser, herunder kognitive lidelser - Google Patents

Biomarkør for mentale lidelser, herunder kognitive lidelser, og fremgangsmåde ved anvendelse af biomarkøren til påvisning af mentale lidelser, herunder kognitive lidelser Download PDF

Info

Publication number
DK2444814T5
DK2444814T5 DK10777546.2T DK10777546T DK2444814T5 DK 2444814 T5 DK2444814 T5 DK 2444814T5 DK 10777546 T DK10777546 T DK 10777546T DK 2444814 T5 DK2444814 T5 DK 2444814T5
Authority
DK
Denmark
Prior art keywords
leu
glu
ala
val
gly
Prior art date
Application number
DK10777546.2T
Other languages
English (en)
Other versions
DK2444814T3 (da
Inventor
Kazuhiko Uchida
Takashi Ishii
Kohji Meno
Hideaki Suzuki
Original Assignee
Mcbi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcbi Inc filed Critical Mcbi Inc
Publication of DK2444814T3 publication Critical patent/DK2444814T3/da
Application granted granted Critical
Publication of DK2444814T5 publication Critical patent/DK2444814T5/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974—Thrombin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Claims (8)

1. Peptid eller protein til anvendelse som en biomarkør til påvisning af en psykiatrisk sygdom eller kognitiv dysfunktion, hvor proteinet er Neurexin-2-beta-præcursor bestående af aminosyresekvensen udtrykt ved SEQ ID NO: 1 eller proteinet er et protein bestående af aminosyresekvensen afledt af SEQ ID NO: 1 ved deletion, udveksling og/eller addition af en til tre aminosyrer, og peptidet er Neurexin-2-beta-præcursor-afledt peptid NRX2B bestående af aminosyresekvensen udtrykt ved SEQ ID NO: 2 eller peptidet er et peptid bestående af en aminosyresekvens afledt af SEQ ID No. 2 ved deletion, udveksling og/eller addition af en til tre aminosyrer.
2. Peptid eller protein ifølge krav 1, hvor peptidet eller proteinet er peptidet til anvendelse som en biomarkør af kognitiv dysfunktion bestående af aminosyresekvensen udtrykt ved SEQ ID NO: 2, som forekommer eller er øget i biologisk materiale hos patienter med kognitiv dysfunktion sammenlignet med biologisk materiale hos individer, der ikke lider af en psykiatrisk sygdom.
3. Peptid eller protein ifølge krav 1, hvor peptidet eller proteinet er peptidet til anvendelse som en biomarkør af Alzheimers sygdom bestående af aminosyresekvensen udtrykt ved SEQ ID NO: 2, som forekommer eller er øget i biologisk materiale hos patienter med Alzheimers sygdom sammenlignet med biologisk materiale hos individer, der ikke lider af en ikke-dement neurologisk sygdom.
4. Peptid eller protein ifølge et af kravene 1 til 3, hvor peptidet har en molekylvægt på mindre end 10000 eller har mindre end 50 aminosyrer.
5. In-vitro-fremgangsmåde til påvisning af en psykiatrisk sygdom eller kognitiv dysfunktion, der indeholder fastlæggelsen i biologisk materiale af mindst et peptid eller protein som beskrevet i krav 1.
6.1 n-vitro-f remgangsmåde ifølge krav 5 til påvisning af kognitiv dysfunktion, ved hvilken en patient bedømmes til at lide af kognitiv dysfunktion, når pepti- det, efter fastlæggelsen i biologisk materiale af peptidet som biomarkør for kognitiv dysfunktion som beskrevet i krav 2, findes at være til stede i en større mængde end i individer, der ikke lider af en psykiatrisk sygdom.
7. Kit til påvisning af en psykiatrisk sygdom indeholdende antistof eller apta-mer, der er specifikt for mindst et peptid eller protein som beskrevet i krav 1, til at fastlægge mindst et peptid eller protein som beskrevet i krav 1.
8. Kit til påvisning af en kognitiv dysfunktion indeholdende antistof eller ap-tamer, der er specifikt for mindst et peptid eller protein som beskrevet i krav 1, til at fastlægge mindst et peptid eller protein som beskrevet i krav 1 eller 2.
DK10777546.2T 2009-05-19 2010-05-17 Biomarkør for mentale lidelser, herunder kognitive lidelser, og fremgangsmåde ved anvendelse af biomarkøren til påvisning af mentale lidelser, herunder kognitive lidelser DK2444814T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009121226A JP2010271078A (ja) 2009-05-19 2009-05-19 認知機能障害疾患を含む精神疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患を含む精神疾患の検出方法
PCT/JP2010/003295 WO2010134308A1 (ja) 2009-05-19 2010-05-17 認知機能障害疾患を含む精神疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患を含む精神疾患の検出方法

Publications (2)

Publication Number Publication Date
DK2444814T3 DK2444814T3 (da) 2017-03-20
DK2444814T5 true DK2444814T5 (da) 2017-10-02

Family

ID=43126001

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10777546.2T DK2444814T5 (da) 2009-05-19 2010-05-17 Biomarkør for mentale lidelser, herunder kognitive lidelser, og fremgangsmåde ved anvendelse af biomarkøren til påvisning af mentale lidelser, herunder kognitive lidelser

Country Status (6)

Country Link
US (3) US8748574B2 (da)
EP (2) EP2444814B9 (da)
JP (1) JP2010271078A (da)
DK (1) DK2444814T5 (da)
ES (1) ES2617918T3 (da)
WO (1) WO2010134308A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010271078A (ja) 2009-05-19 2010-12-02 Mcbi:Kk 認知機能障害疾患を含む精神疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患を含む精神疾患の検出方法
JP6012923B2 (ja) * 2010-12-22 2016-10-25 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
GB201310150D0 (en) * 2013-06-07 2013-07-24 Electrophoretics Ltd Methods and compositions relating to alzheimer's disease
SG11201510701QA (en) 2013-06-28 2016-01-28 Mcbi Inc Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
CN105067817B (zh) * 2015-07-08 2017-05-10 上海清流生物医药科技有限公司 感光芯片采集信号的方法和装置及追踪细胞的方法和装置
UY37376A (es) * 2016-08-26 2018-03-23 Amgen Inc Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
US11543418B2 (en) 2017-07-13 2023-01-03 Kazuhiko Uchida Biomarker for cognitive dysfunction disease and method for detecting cognitive dysfunction disease using biomarker
WO2019013341A1 (ja) * 2017-07-14 2019-01-17 株式会社島津製作所 疾患検出方法
JP2019020206A (ja) 2017-07-14 2019-02-07 株式会社島津製作所 質量分析を用いた認知機能障害疾患バイオマーカーの定量方法及び質量分析装置
KR20260000666A (ko) * 2024-06-25 2026-01-05 가톨릭대학교 산학협력단 뇌신경계 질환 진단 또는 예후 예측용 바이오마커 조성물 및 이를 이용한 진단 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020037528A1 (en) * 1999-08-13 2002-03-28 Berg David E. Method for detecting procoagulant genetic and metabolic conditions associated with, and potentially predispositional for, activation of the coagulation response
GB2368642B (en) * 1999-08-13 2004-07-07 David E Berg Method for detecting, treating, and monitoring conditions associated with activation of the coagulation response
EP1497319A2 (en) 2001-05-02 2005-01-19 Incyte Genomics, Inc. Cell adhesion and extracellular matrix proteins
US20040101874A1 (en) * 2002-04-12 2004-05-27 Mitokor Inc. Targets for therapeutic intervention identified in the mitochondrial proteome
WO2004001421A2 (en) 2002-06-21 2003-12-31 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
CA2745998C (en) * 2002-08-23 2013-11-26 Bayer Schering Pharma Aktiengesellschaft Biomarkers for diagnosing alzheimer's disease
JP4170139B2 (ja) 2003-05-07 2008-10-22 財団法人癌研究会 血清アポリポタンパク質ａ−ｉｉ量変化の検出方法
US7598049B2 (en) * 2003-11-19 2009-10-06 Satoris, Inc. Methods for diagnosis of Alzheimer's Disease in blood samples
WO2005115478A2 (en) * 2004-05-11 2005-12-08 The Regents Of The University Of California Methods and compositions for autism spectrum disorders
GB0421639D0 (en) * 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
JP4801930B2 (ja) 2005-05-02 2011-10-26 株式会社Ｍｃｂｉ 新規肝がんバイオマーカーおよび該バイオマーカーを用いた肝がんの検出方法
WO2006121952A2 (en) * 2005-05-05 2006-11-16 The Regents Of The University Of California Diagnostic biomarkers for neurodevelopmental disorders
EP1949123A2 (en) * 2005-10-18 2008-07-30 Cambridge Enterprise Limited Methods and biomarkers for diagnosing and monitoring psychotic disorders
JP5219819B2 (ja) * 2005-10-21 2013-06-26 カタリスト・バイオサイエンシーズ・インコーポレイテッド 補体活性化を阻害する修飾プロテアーゼ
US20080199426A1 (en) * 2007-01-11 2008-08-21 Sukhatme Vikas P Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
GB0701626D0 (en) * 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
JP2010271078A (ja) 2009-05-19 2010-12-02 Mcbi:Kk 認知機能障害疾患を含む精神疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患を含む精神疾患の検出方法

Also Published As

Publication number Publication date
EP2444814A4 (en) 2013-03-20
US11726099B2 (en) 2023-08-15
EP2444814B1 (en) 2016-12-28
WO2010134308A1 (ja) 2010-11-25
EP3088899A1 (en) 2016-11-02
EP3088899B1 (en) 2018-01-17
DK2444814T3 (da) 2017-03-20
US20200057079A1 (en) 2020-02-20
EP2444814A1 (en) 2012-04-25
US20120149034A1 (en) 2012-06-14
ES2617918T9 (es) 2018-02-16
JP2010271078A (ja) 2010-12-02
US8748574B2 (en) 2014-06-10
US20140378325A1 (en) 2014-12-25
ES2617918T3 (es) 2017-06-20
EP2444814B9 (en) 2017-08-09

Similar Documents

Publication Publication Date Title
US11726099B2 (en) Biomarker for mental disorders including cognitive disorders, and method using said biomarker to detect mental disorders including cognitive disorders
US11307208B2 (en) Biomarkers for cognitive impairment and methods for detecting cognitive impairment using such biomarkers
JP6113798B2 (ja) 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
EP3654038B1 (en) Biomarker for cognitive impairment disorders and detection method for cognitive impairment disorders using said biomarker
JP6408087B2 (ja) 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
JP6359158B2 (ja) 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
JP6193942B2 (ja) 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
JP2012037349A (ja) 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患の検出方法
JP6359159B2 (ja) 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法